- Home
- KUKE vs SNTI Comparison
KUKE vs SNTI Comparison
Compare KUKE & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- SNTI
- Stock Information
- Founded
- KUKE 2002
- SNTI 2016
- Country
- KUKE China
- SNTI United States
- Employees
- KUKE N/A
- SNTI 48
- Industry
- KUKE Other Consumer Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- SNTI Health Care
- Exchange
- KUKE Nasdaq
- SNTI Nasdaq
- Market Cap
- KUKE 86.8M
- SNTI 50.3M
- IPO Year
- KUKE 2021
- SNTI N/A
- Fundamental
- Price
- KUKE $2.62
- SNTI $1.93
- Analyst Decision
- KUKE
- SNTI Strong Buy
- Analyst Count
- KUKE 0
- SNTI 2
- Target Price
- KUKE N/A
- SNTI $8.50
- AVG Volume (30 Days)
- KUKE 9.5K
- SNTI 514.4K
- Earning Date
- KUKE 08-05-2025
- SNTI 08-12-2025
- Dividend Yield
- KUKE N/A
- SNTI N/A
- EPS Growth
- KUKE N/A
- SNTI N/A
- EPS
- KUKE N/A
- SNTI N/A
- Revenue
- KUKE $9,442,397.00
- SNTI N/A
- Revenue This Year
- KUKE N/A
- SNTI N/A
- Revenue Next Year
- KUKE N/A
- SNTI $150.00
- P/E Ratio
- KUKE N/A
- SNTI N/A
- Revenue Growth
- KUKE N/A
- SNTI N/A
- 52 Week Low
- KUKE $1.45
- SNTI $1.52
- 52 Week High
- KUKE $17.50
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- KUKE 29.13
- SNTI 37.06
- Support Level
- KUKE $2.58
- SNTI $1.86
- Resistance Level
- KUKE $2.96
- SNTI $2.12
- Average True Range (ATR)
- KUKE 0.14
- SNTI 0.16
- MACD
- KUKE -0.03
- SNTI 0.03
- Stochastic Oscillator
- KUKE 20.63
- SNTI 24.24
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.